https://www.selleckchem.com/pr....oducts/favipiravir-t
05), and ARRs were 0.12 versus 0.30 (p=.05). 45% of Glatopa patients switched (back) to Copaxone 20/40mg and were censored at that point. Mean (SD) all-cause medical and pharmacy costs were $51,507 ($28,494) versus $55,085 ($37,061; p=.5. Mean MS-related costs were $45,379 ($24,732) versus $47,949 ($32,615; p=.67), of which mean disease modifying therapy costs were $42,926 ($23,196) versus $44,932 ($28,554; p=.59). Results were similar in sensitivity analyses.Conclusions In this real-world study, MS patients treated with Gla